Objective: The aim of this study was to identify and determine the in vitro antifungal susceptibility testing to clotrimazole, fluconazole, and nystatin of 145 clinical isolates of Candida spp.
Methods: M27-A3 microdilution method was used to determine minimal inhibitory concentrations (MIC) and partial MICs (MIC50 and MIC90) of drugs. A total of 145 isolates were studied, 126 were C. albicans, 16 C. glabrata, 2 C. parapsilosis y 1 C. tropicalis.
Results: MIC50 and MIC90 for FLZ against C. albicans were 0.25 mg/L and 1 mg/L respectively and for C. glabrata was achieved at 8 mg/L and 16 mg/L for fluconazole. Five isolates of C. albicans and one isolate of C. tropicalis were in vitro resistant to fluconazole (M27-S4). In C. albicans MIC50 and MIC90 for clotrimazole were of 0.03 mg/L and 0.06 mg/L, respectively. These values for C. glabrata were 0.25 mg/L and 1 mg/L, respectively. Five C. glabrata and 1 C. tropicalis were in vitro resistant to clotrimazole. MIC50 and MIC90 of nystatin were of 1 mg/L and 2 mg/L, respectively for C. albicans and C. glabrata.
Conclusions: In this study, C. albicans is the most frequently isolated yeast, followed by C. glabrata. The antifungals tested were found to be in vitro active for the isolates, except for 6 isolates for fluconazole and 6 to clotrimazole.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In vitro activity of omadacycline against geographically diverse rapidly growing nontuberculous mycobacteria (NTM) clinical isolates.
Diagn Microbiol Infect Dis
December 2024
Department of Medical Microbiology, Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
Nontuberculous mycobacteria (NTM) are emerging opportunistic pathogens with limited treatment options due to resistance to multiple antibiotic classes. This study aimed to evaluate the in vitro activity of omadacycline and comparator antibiotics against rapidly growing mycobacteria (RGM) clinical isolates. Minimum inhibitory concentration (MIC) evaluation of RGM clinical isolates was performed by two independent laboratories (EU and Japan).
View Article and Find Full Text PDFUnraveling Antimicrobial Resistance Dynamics in Mycoplasma gallisepticum: Insights Into Antibiotic and Disinfectant Interactions.
Vet Med Sci
January 2025
Department of Veterinary Hygiene and Management, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
A major risk to the poultry industry is antimicrobial resistance (AMR), specifically with regard to Mycoplasma gallisepticum (MG) infections. The sensitivity patterns of 100 MG isolates to biocides and antibiotics were examined in this study to clarify the interactions between antimicrobial agents and resistance mechanisms. The antimicrobial activity against MG was assessed using broth microdilution, and the results are shown as the minimum inhibitory concentration (MIC) for each strain, the MIC distribution (range), the MIC, and/or the MIC.
View Article and Find Full Text PDFAztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.
J Antibiot (Tokyo)
January 2025
Department of Microbiology, Nicolaus Copernicus University, The Ludwik Rydygiers Collegium Medicum, Bydgoszcz, Poland.
Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor.
View Article and Find Full Text PDFIn vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) including hVISA isolates collected across India.
Indian J Med Microbiol
January 2025
Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India; Central Research Lab, Sri Venkateswaraa Medical College Hospital and Research Centre, Ariyur, Puducherry, India. Electronic address:
Background: Vancomycin has been the preferred treatment for MRSA infections. However, newer drugs are necessary due to the increasing prevalence of MRSA isolates that are less susceptible to vancomycin. Levonadifloxacin and its prodrug alalevonadifloxacin, novel quinolones with broad spectrum anti-MRSA activity.
View Article and Find Full Text PDFIn vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.
J Antimicrob Chemother
December 2024
Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health, Denver, CO, USA.
Background: Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!